AbbVie Group Leader (m/w) in vivo Biology core and Neuroanatomy in Ludwigshafen, Germany
Group Leader (m/w) in vivo Biology core and Neuroanatomy
Germany, Rhinland-Palatinate, Ludwigshafen
Research & Development
Contributes to and drives overall in vivo pharmacology experimental strategy and execution for preferentially late stage discovery pipeline projects in the area of neurodegenerative diseases with a primary focus on Alzheimer’s - and Parkinson’s disease by generating profiling and translational data sets to stage-gate-appropriate data packages for further and timely advancement. Accountable for the timely advancement of early and late stage discovery programs consistent with therapeutic area preclinical and clinical project director plans and expectations. Represents Ludwigshafen in in vivo pharmacology directly or indirectly through delegates to the project teams, the head of discovery biology, the head of discovery, group leader peers and other senior leaders, clearly communicating in vivo pharmacology plans, issues, opportunities, and resourcing.
Enables cross-functional interaction (local and global) of LU-Discovery in vivo pharmacology with other parts of the Neurology Discovery organization to ensure adequate resourcing with in vivo pharmacology capacities for effective project transitions according to the PD progression plans.
Ensures the effective characterization and profiling of tools, leads and potential clinical candidates by applying animal model research for the areas of focus (Alzheimer’s and Parkinson’s disease), also in alignment with the Foundational Neuroscience Center in Cambridge US to complement the activities as needed to adequately populate the preclinical discovery neurology portfolio.
Enables a data-driven prioritization by contributing in vivo data sets to support the advancement of the neurology pipeline.
Contributes to the scientific assessment of internal and external neurology collaborative opportunities in close interaction with the disease area experts and other functionalities as appropriate.
Coordinates external collaborations on in vivo exploration with key experts, project directors and CROs as needed to facilitate the advancement of the neurology pipeline.
Represents Exploratory Neurology in vivo pharmacology to internal and external parties
Drives and enables scientific excellence, technology advancement and experimental standards for in vivo exploration and selection/prioritization of animal models for the areas of focus
Directly leads a team of highly skilled in vivo experimental experts (up to 6 FTE) which can be expanded by post-docs and trainees, indirectly leads a neuroanatomy team and an in vivo/ex vivo biochemistry team which are part of the group.
- PhD or equivalent, managerial experience, 8-10 yrs postdoc/industry experience
Demonstrated excellence and success in leading an in vivo pharmacology team in neurodegenerative diseases with focus on Alzheimer’s and/or Parkinson’s disease
Contribution by in vivo pharmacology to milestones or timely stop decisions
Demonstrated ability to in vivo profiling of tools, drug leads and potential clinical candidates
Proven track record in neurodegenerative diseases; ideally AD and/or PD
Key AbbVie Competencies:
Builds strong relationships with peers and cross functionally with partners (local and global) outside of team to enable higher performance.
Is a team player on all levels with a broader global view
Learns fast, grasps the "essence" and can change course quickly where indicated
Raises the bar and is never satisfied with the status quo
Creates a learning environment, open to suggestions and experimentation for improvement
Embraces the ideas of others, nurtures innovation and manages innovation to reality
We are looking forward to your application. Please provide information about your salary expectations and possible start date in your motivation letter.
An equal opportunity employer. AbbVie welcomes and encourages diversity in our workforce.
Learn more about AbbVie Deutschland at www.abbvie.de . Visit www.abbvie-care.de for more information about the therapeutic areas in which we’re active.